Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levilimab
- Development stage
- Phase 3
- Lead developer
- Biocad
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Levilimab is a fully human monoclonal antibody that acts as an antagonist of the interleukin 6 receptor (IL-6R). It was originally developed for the treatment of rheumatoid arthritis, particularly in patients resistant to methotrexate monotherapy. Levilimab inhibits IL-6 signaling, thereby reducing inflammation and modulating immune responses. It has also been investigated for use in severe COVID-19 to mitigate cytokine storm effects and improve clinical outcomes. The drug is administered either intravenously or subcutaneously and has demonstrated efficacy and safety in phase III clinical trials for both rheumatoid arthritis and severe COVID-19[1][3][7][10].
- Brand names
- Ilsira
- Other names
- levilimabBCD 089BCD089BCD-089Ilsira
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)
Beyond the preview
Go deeper on levilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levilimab.